Cargando…
LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
Individuals with LPIN1 deficiency have early recurrent, life-threatening rhabdomyolysis but the full phenotypic spectrum and optimal treatment of the disorder remains unknown. Here we report the clinical details and treatment outcomes of 6 patients from our health system. The average age of presenta...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856908/ https://www.ncbi.nlm.nih.gov/pubmed/35242575 http://dx.doi.org/10.1016/j.ymgmr.2022.100844 |
_version_ | 1784653942760669184 |
---|---|
author | Kanderi, Navya Kirmse, Brian Regier, Debra S. Chapman, Kimberly A. |
author_facet | Kanderi, Navya Kirmse, Brian Regier, Debra S. Chapman, Kimberly A. |
author_sort | Kanderi, Navya |
collection | PubMed |
description | Individuals with LPIN1 deficiency have early recurrent, life-threatening rhabdomyolysis but the full phenotypic spectrum and optimal treatment of the disorder remains unknown. Here we report the clinical details and treatment outcomes of 6 patients from our health system. The average age of presentation in our cohort was 23.8 months ±11.6 months (range 15–46 months). The average number of days for each hospitalization for this cohort is 11.7±13.2 days. Creatinine kinase (CK) levels peak during our care averaged 607,725 units/L (range 157,000-1,100,000 units/L). We observed that aspartate aminotransferase levels paralleled the CK levels in its elevation and resolution (Pearson's correlation R = 0.995); while alanine aminotransferase paralleled the elevation but lagged in the resolution of CK levels (R = 0.728). Unlike historical accounts, in our patient population, rhabdomyolysis was sometimes seen without inciting viral or traumatic events. We also cared for multiple individuals that had received treatment at other centers. This allowed us to compare multiple practice approaches and led to a standardized Care Recommendations. |
format | Online Article Text |
id | pubmed-8856908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88569082022-03-02 LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations Kanderi, Navya Kirmse, Brian Regier, Debra S. Chapman, Kimberly A. Mol Genet Metab Rep Research Paper Individuals with LPIN1 deficiency have early recurrent, life-threatening rhabdomyolysis but the full phenotypic spectrum and optimal treatment of the disorder remains unknown. Here we report the clinical details and treatment outcomes of 6 patients from our health system. The average age of presentation in our cohort was 23.8 months ±11.6 months (range 15–46 months). The average number of days for each hospitalization for this cohort is 11.7±13.2 days. Creatinine kinase (CK) levels peak during our care averaged 607,725 units/L (range 157,000-1,100,000 units/L). We observed that aspartate aminotransferase levels paralleled the CK levels in its elevation and resolution (Pearson's correlation R = 0.995); while alanine aminotransferase paralleled the elevation but lagged in the resolution of CK levels (R = 0.728). Unlike historical accounts, in our patient population, rhabdomyolysis was sometimes seen without inciting viral or traumatic events. We also cared for multiple individuals that had received treatment at other centers. This allowed us to compare multiple practice approaches and led to a standardized Care Recommendations. Elsevier 2022-02-05 /pmc/articles/PMC8856908/ /pubmed/35242575 http://dx.doi.org/10.1016/j.ymgmr.2022.100844 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Paper Kanderi, Navya Kirmse, Brian Regier, Debra S. Chapman, Kimberly A. LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations |
title | LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations |
title_full | LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations |
title_fullStr | LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations |
title_full_unstemmed | LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations |
title_short | LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations |
title_sort | lpin1 rhabdomyolysis: a single site cohort description and treatment recommendations |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856908/ https://www.ncbi.nlm.nih.gov/pubmed/35242575 http://dx.doi.org/10.1016/j.ymgmr.2022.100844 |
work_keys_str_mv | AT kanderinavya lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations AT kirmsebrian lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations AT regierdebras lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations AT chapmankimberlya lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations |